Country: United States
Language: English
Source: NLM (National Library of Medicine)
TROSPIUM CHLORIDE (UNII: 1E6682427E) (TROSPIUM - UNII:T4Y8ORK057)
AvKARE
TROSPIUM CHLORIDE
TROSPIUM CHLORIDE 20 mg
ORAL
PRESCRIPTION DRUG
Trospium chloride tablets, USP are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Trospium chloride tablets are contraindicated in patients with: - urinary retention - gastric retention - uncontrolled narrow-angle glaucoma. - known hypersensitivity to the drug or its ingredients. Angioedema, rash and anaphylactic reaction have been reported. Teratogenic Effects Pregnancy Category C: There are no adequate and well-controlled studies of trospium chloride tablets in pregnant women. Trospium chloride tablets should be used during pregnancy only if the potential benefit to the patient outweighs the risk to the patient and fetus. Women who become pregnant during trospium chloride treatment are encouraged to contact their physician. Risk Summary Based on animal data, trospium chloride tablets are predicted to have a low probability of increased risk of adverse developmental outcomes, above b
Trospium chloride tablets, USP 20 mg (brownish-yellow, round, biconvex, film-coated tablets, engraved “APO” on one side and “TR” over “20” on the other side) are supplied as follows: Bottles of 60 NDC 42291-846-60 Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
Abbreviated New Drug Application
TROSPIUM CHLORIDE- TROSPIUM CHLORIDE TABLET AVKARE ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION TROSPIUM CHLORIDE TABLET, USP RX ONLY THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE TROSPIUM CHLORIDE TABLETS, USP SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR TROSPIUM CHLORIDE TABLETS, USP. TROSPIUM CHLORIDE TABLETS, USP, FOR ORAL USE INITIAL U.S. APPROVAL: 2004 RECENT MAJOR CHANGES Warnings and Precautions, Central Nervous System Effects ( 5.5) 07/2012 INDICATIONS AND USAGE Trospium chloride tablets, USP are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1) DOSAGE AND ADMINISTRATION The recommended dose of trospium chloride is one 20 mg tablet twice daily. Trospium chloride tablets should be dosed with water on an empty stomach, at least one hour before a meal. ( 2) For patients with severe renal impairment (creatinine clearance less than 30 mL/min), the recommended dose is 20 mg once daily at bedtime. ( 2) In geriatric patients greater than or equal to 75 years of age, dose may be titrated down to 20 mg once daily based upon tolerability. ( 2) DOSAGE FORMS AND STRENGTHS 20 mg tablets. ( 3) CONTRAINDICATIONS Trospium chloride tablets are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma, and in patients who are at risk for these conditions ( 4) patients with known hypersensitivity ( 4) WARNINGS AND PRECAUTIONS Trospium chloride tablets should be administered with caution to patients with clinically significant bladder outflow obstruction or gastrointestinal obstructive disorders due to risk of urinary or gastric retention. ( 5.1, 5.3) Angioedema of the face, lips, tongue and/or larynx has been reported with trospium chloride. ( 5.2) In patients with controlled narrow angle glaucoma trospium chloride tablets should be used only with careful monitoring. ( 5.4) Central Nervous System Effects: Somnolence has been Read the complete document